Therapeutic progress has accelerated, with multiple recent approvals improving outcomes across early-stage, muscle-invasive, and metastatic urothelial carcinoma. FGFR3 and HER2 protein expression by ...
Targeted MAPK pathway inhibition with atebimetinib contrasts with nonselective cytotoxic chemotherapy and is paired with a dose-schedule modification intended to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果